Literature DB >> 19005480

Telomere length is severely and similarly reduced in JAK2V617F-positive and -negative myeloproliferative neoplasms.

L Bernard1, C Belisle, L Mollica, S Provost, D-C Roy, D G Gilliland, R L Levine, L Busque.   

Abstract

Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized by chronic proliferation of hematopoietic progenitors. We studied the telomere length (TL) of 335 MPN patients and 93 gender- and age-matched controls using a quantitative PCR method (relative TL calculated as the ratio of the amount of telomere DNA vs single-copy DNA: T/S ratio). TL was markedly reduced in MPN patients compared with controls (T/S 0.561 vs 0.990, P<0.001). In JAK2V617F MPN patients, TL correlated inversely with allelic burden (P<0.001). Patients homozygous for the mutation (allelic burden 90-100%) had the shortest TL, even when compared with patients with lower allele burdens consistent with a dominant heterozygous population (allelic burden 55-65%) (T/S 0.367 vs 0.497, P=0.037). This suggests that the high degree of proliferation of the MPN clone reduces TL and suggests the possibility that TL shortening may be indicative of progressive genomic instability during MPN progression. The TL of JAK2V617F-negative MPN patients was similar to JAK2V617F-positive counterparts (T/S 0.527 vs 0.507, P=0.603), suggesting that the yet-to-be-discovered causative mutation(s) impact the mutated stem cell similarly to JAK2V617F, and that TL measurement may prove useful in the diagnostic workup of JAK2V617F-negative MPN.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19005480      PMCID: PMC4640467          DOI: 10.1038/leu.2008.319

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  36 in total

1.  Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry.

Authors:  T H Brümmendorf; T L Holyoake; N Rufer; M J Barnett; M Schulzer; C J Eaves; A C Eaves; P M Lansdorp
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

Review 2.  Telomeres as biomarkers for ageing and age-related diseases.

Authors:  T von Zglinicki; C M Martin-Ruiz
Journal:  Curr Mol Med       Date:  2005-03       Impact factor: 2.222

3.  X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.

Authors:  Ross L Levine; Claude Belisle; Martha Wadleigh; David Zahrieh; Stephanie Lee; Pierre Chagnon; D Gary Gilliland; Lambert Busque
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

4.  Clonal granulocytes in polycythaemia vera and essential thrombocythaemia have shortened telomeres.

Authors:  Anna Maria Ferraris; Natalija Pujic; Rosa Mangerini; Davide Rapezzi; Andrea Gallamini; Omar Racchi; Salvatore Casciaro; Gian Franco Gaetani
Journal:  Br J Haematol       Date:  2005-08       Impact factor: 6.998

Review 5.  Telomeres and human disease: ageing, cancer and beyond.

Authors:  Maria A Blasco
Journal:  Nat Rev Genet       Date:  2005-08       Impact factor: 53.242

6.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

7.  Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age.

Authors:  L Busque; R Mio; J Mattioli; E Brais; N Blais; Y Lalonde; M Maragh; D G Gilliland
Journal:  Blood       Date:  1996-07-01       Impact factor: 22.113

8.  Application of carrier testing to genetic counseling for X-linked agammaglobulinemia.

Authors:  R C Allen; R G Nachtman; H M Rosenblatt; J W Belmont
Journal:  Am J Hum Genet       Date:  1994-01       Impact factor: 11.025

9.  X-chromosome inactivation patterns using HPRT and PGK polymorphisms in haematologically normal and post-chemotherapy females.

Authors:  R E Gale; H Wheadon; D C Linch
Journal:  Br J Haematol       Date:  1991-10       Impact factor: 6.998

10.  Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

Authors:  Alexandre Theocharides; Marjorie Boissinot; François Girodon; Richard Garand; Soon-Siong Teo; Eric Lippert; Pascaline Talmant; Andre Tichelli; Sylvie Hermouet; Radek C Skoda
Journal:  Blood       Date:  2007-03-15       Impact factor: 22.113

View more
  10 in total

1.  Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms.

Authors:  Chiara Elena; Elisa Rumi; Monica Portolan; Matteo G Della Porta; Cristiana Pascutto; Francesco Passamonti
Journal:  Haematologica       Date:  2011-08       Impact factor: 9.941

2.  Dysregulation of shelterin factors coupled with telomere shortening in Philadelphia chromosome negative myeloproliferative neoplasms.

Authors:  Jenny Dahlström; Xiaolu Zhang; Mehran Ghaderi; Malin Hultcrantz; Magnus Björkholm; Dawei Xu
Journal:  Haematologica       Date:  2015-07-16       Impact factor: 9.941

Review 3.  Pharmacotherapy of Myelofibrosis.

Authors:  Douglas Tremblay; Bridget Marcellino; John Mascarenhas
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

4.  Telomerase inhibition effectively targets mouse and human AML stem cells and delays relapse following chemotherapy.

Authors:  Claudia Bruedigam; Frederik O Bagger; Florian H Heidel; Catherine Paine Kuhn; Solene Guignes; Axia Song; Rebecca Austin; Therese Vu; Erwin Lee; Sarbjit Riyat; Andrew S Moore; Richard B Lock; Lars Bullinger; Geoffrey R Hill; Scott A Armstrong; David A Williams; Steven W Lane
Journal:  Cell Stem Cell       Date:  2014-12-04       Impact factor: 24.633

5.  Ruxolitinib therapy and telomere length in myelofibrosis.

Authors:  G Caocci; M Greco; G Delogu; C Secchi; A Perra; S Ghiani; F Orru; A Vacca; F Galimi; G La Nasa
Journal:  Blood Cancer J       Date:  2016-10-07       Impact factor: 11.037

6.  Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential.

Authors:  Tetsushi Nakao; Alexander G Bick; Margaret A Taub; Seyedeh M Zekavat; Md M Uddin; Abhishek Niroula; Cara L Carty; John Lane; Michael C Honigberg; Joshua S Weinstock; Akhil Pampana; Christopher J Gibson; Gabriel K Griffin; Shoa L Clarke; Romit Bhattacharya; Themistocles L Assimes; Leslie S Emery; Adrienne M Stilp; Quenna Wong; Jai Broome; Cecelia A Laurie; Alyna T Khan; Albert V Smith; Thomas W Blackwell; Veryan Codd; Christopher P Nelson; Zachary T Yoneda; Juan M Peralta; Donald W Bowden; Marguerite R Irvin; Meher Boorgula; Wei Zhao; Lisa R Yanek; Kerri L Wiggins; James E Hixson; C Charles Gu; Gina M Peloso; Dan M Roden; Muagututi'a S Reupena; Chii-Min Hwu; Dawn L DeMeo; Kari E North; Shannon Kelly; Solomon K Musani; Joshua C Bis; Donald M Lloyd-Jones; Jill M Johnsen; Michael Preuss; Russell P Tracy; Patricia A Peyser; Dandi Qiao; Pinkal Desai; Joanne E Curran; Barry I Freedman; Hemant K Tiwari; Sameer Chavan; Jennifer A Smith; Nicholas L Smith; Tanika N Kelly; Bertha Hidalgo; L Adrienne Cupples; Daniel E Weeks; Nicola L Hawley; Ryan L Minster; Ranjan Deka; Take T Naseri; Lisa de Las Fuentes; Laura M Raffield; Alanna C Morrison; Paul S Vries; Christie M Ballantyne; Eimear E Kenny; Stephen S Rich; Eric A Whitsel; Michael H Cho; M Benjamin Shoemaker; Betty S Pace; John Blangero; Nicholette D Palmer; Braxton D Mitchell; Alan R Shuldiner; Kathleen C Barnes; Susan Redline; Sharon L R Kardia; Gonçalo R Abecasis; Lewis C Becker; Susan R Heckbert; Jiang He; Wendy Post; Donna K Arnett; Ramachandran S Vasan; Dawood Darbar; Scott T Weiss; Stephen T McGarvey; Mariza de Andrade; Yii-Der Ida Chen; Robert C Kaplan; Deborah A Meyers; Brian S Custer; Adolfo Correa; Bruce M Psaty; Myriam Fornage; JoAnn E Manson; Eric Boerwinkle; Barbara A Konkle; Ruth J F Loos; Jerome I Rotter; Edwin K Silverman; Charles Kooperberg; John Danesh; Nilesh J Samani; Siddhartha Jaiswal; Peter Libby; Patrick T Ellinor; Nathan Pankratz; Benjamin L Ebert; Alexander P Reiner; Rasika A Mathias; Ron Do; Pradeep Natarajan
Journal:  Sci Adv       Date:  2022-04-06       Impact factor: 14.957

7.  TERT rs2736100 genotypes are associated with differential risk of myeloproliferative neoplasms in Swedish and Chinese male patient populations.

Authors:  Jenny Dahlström; Tiantian Liu; Xiaotian Yuan; Leonie Saft; Mehran Ghaderi; Ya Bin Wei; Catharina Lavebratt; Ping Li; Chengyun Zheng; Magnus Björkholm; Dawei Xu
Journal:  Ann Hematol       Date:  2016-08-25       Impact factor: 3.673

8.  Immortalization of human AE pre-leukemia cells by hTERT allows leukemic transformation.

Authors:  Shan Lin; Junping Wei; Mark Wunderlich; Fu-Sheng Chou; James C Mulloy
Journal:  Oncotarget       Date:  2016-08-30

9.  Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project.

Authors:  Daniela Barraco; Barbara Mora; Paola Guglielmelli; Elisa Rumi; Margherita Maffioli; Alessandro Rambaldi; Marianna Caramella; Rami Komrokji; Jason Gotlib; Jean Jacques Kiladjian; Francisco Cervantes; Timothy Devos; Francesca Palandri; Valerio De Stefano; Marco Ruggeri; Richard T Silver; Giulia Benevolo; Francesco Albano; Michele Merli; Daniela Pietra; Tiziano Barbui; Giada Rotunno; Mario Cazzola; Toni Giorgino; Alessandro Maria Vannucchi; Francesco Passamonti
Journal:  Blood Cancer J       Date:  2018-09-21       Impact factor: 11.037

10.  Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms.

Authors:  Matteo Giaccherini; Angelica Macauda; Nicola Sgherza; Juan Sainz; Federica Gemignani; Josè Manuel Sanchez Maldonado; Manuel Jurado; Francesca Tavano; Grzegorz Mazur; Andrés Jerez; Joanna Góra-Tybor; Aleksandra Gołos; Francisca Hernández Mohedo; Joaquin Martinez Lopez; Judit Várkonyi; Raffaele Spadano; Aleksandra Butrym; Federico Canzian; Daniele Campa
Journal:  Blood Cancer J       Date:  2020-09-01       Impact factor: 11.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.